Compare PFX & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | XTNT |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.5M | 68.9M |
| IPO Year | N/A | 2009 |
| Metric | PFX | XTNT |
|---|---|---|
| Price | $45.50 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 4.1K | ★ 146.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.30 | $0.44 |
| 52 Week High | $53.59 | $0.95 |
| Indicator | PFX | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 37.10 |
| Support Level | $42.28 | $0.44 |
| Resistance Level | $46.69 | $0.67 |
| Average True Range (ATR) | 0.96 | 0.02 |
| MACD | 0.50 | 0.00 |
| Stochastic Oscillator | 100.00 | 29.43 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.